Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alcon AG(ALC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALC
09/25/2026: ALC (1-star) is currently NOT-A-BUY. Pass it for now.
Alcon AG is a global leader in eye care, operating as a pure-play medical device company with two primary segments: surgical equipment and vision care. The firm has a leading position in the cataract and contact lens markets, benefiting from durable demand driven by an aging global population and recurring revenue from consumables. Its primary growth opportunity lies in the continued adoption of premium surgical technologies and recent expansion into ophthalmic pharmaceuticals. However, risks include intense competition from industry giants and sensitivity to elective procedure volumes. The stock may best suit investors seeking a specialized, defensive healthcare play, with key developments to monitor including product innovation success and surgical procedure trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Alcon provides steady growth through the aging demographic and surgical innovation trend. |
| Momentum investor | Mixed fit | Momentum depends on market sentiment regarding elective surgery volume and innovation success. |
| Value investor | Mixed fit | The stock often commands a premium multiple consistent with its high-quality medical franchise. |
| Dividend investor | Mixed fit | Alcon offers a modest dividend, though not typically chosen as a high-yield income play. |
| Low-risk investor | Strong fit while signal remains positive | The medical device sector is generally considered defensive, providing stable demand even in volatile markets. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Broader market conditions and elective surgery trends can lead to short-term stock price fluctuations. |
| Valuation risk | Medium | Investors should monitor if the premium valuation accurately reflects future growth potential. |
| Competition risk (Medical Device) | Medium / high | Constant pressure from JNJ and other innovators requires continuous R&D success to maintain market share. |
| Business quality | Strong | Alcon maintains a deep moat through its established installed base of surgical equipment and brand loyalty. |
| Dividend income | Low | Dividends are reliable but represent a secondary part of total return compared to capital growth. |
| Execution risk | Medium | Success depends on the effective rollout of new surgical systems and maintaining supply chain stability. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -28.56% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 31.16B USD | Price to earnings Ratio 49.21 | 1Y Target Price 84.45 |
Price to earnings Ratio 49.21 | 1Y Target Price 84.45 | ||
Volume (30-day avg) 1.5M shares | Beta 0.7 | 52 Weeks Range 61.84 - 87.22 | Updated Date 09/27/2026 |
52 Weeks Range 61.84 - 87.22 | Updated Date 09/27/2026 | ||
Dividends yield (FY) 0.56% | Basic EPS (TTM) 1.31 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Surgical | Cataract equipment (Centurion), IOLs (PanOptix), and vitreoretinal tools. | Selling the machines and the disposable parts used in eye surgeries provides a steady, high-margin revenue stream. |
| Vision Care | Dailies Total1 lenses and lens care solutions. | This is a recurring, consumer-driven business that benefits from long-term brand loyalty. |
| Geography | Global sales across North America, EMEA, and Asia-Pacific. | A balanced global presence helps buffer the company against regional economic weaknesses. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 49.21 | Forward PE 16.23 | Enterprise Value 35.65B | Price to Sales(TTM) 2.87 |
Enterprise Value 35.65B | Price to Sales(TTM) 2.87 | ||
Enterprise Value to Revenue 3.28 | Enterprise Value to EBITDA 13.07 | Shares Outstanding 483.40M | Shares Floating 481.83M |
Shares Outstanding 483.40M | Shares Floating 481.83M | ||
Percent Insiders 0.2 | Percent Institutions 63.74 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Alcon AG
Exchange NYSE | Headquarters - | ||
IPO Launch date 2019-04-09 | CEO & Director Mr. David J. Endicott | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 25000 | Website https://www.alcon.com |
Full time employees 25000 | Website https://www.alcon.com | ||
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.